| Literature DB >> 32127930 |
Hai Hu1, Wenzhi Tu2, Yungu Chen1, Ming Zhu3, Huan Jin4, Ting Huang4, Zhengzhi Zou4, Qing Xia1.
Abstract
Macrophages play a critical role in the initiation and progression in various human solid tumors; however, their role and transformation in pancreatic ductal adenocarcinoma (PDAC) were still illusive. Here, immunohistochemistry was used to determine CD206 (specific marker of M2 macrophage) and PKM2 expression in PDAC tissues. Statistical analysis, such as Pearson χ2 test, Spearman's rank test, Kaplan-Meier and COX regression assay were used to evaluate their roles on PDAC prognosis. Data showed that both CD206 and PKM2 were elevated and responsible for a poor prognosis for PDAC. In addition, we showed that the two factors were positively correlated; co-overexpression of the two factors conferred the worst prognosis and functioned as an independent prognostic factor for the disease. Our data showed that M2 macrophage infiltration was correlated with PKM2 expression in PDAC cells. The two markers exerted synergistic effect on PDAC progression. Our results suggested dual-target inhibition M2 macrophage polarization and PKM2 expression of cancer cells might be novel approaches to treat PDAC. © The author(s).Entities:
Keywords: PDAC; PKM2; macrophage; prognosis
Year: 2020 PMID: 32127930 PMCID: PMC7052945 DOI: 10.7150/jca.38981
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Baseline features of the patients
| Factor | Number | |
|---|---|---|
| Male | 51 | |
| Female | 26 | |
| ≥60 | 51 | |
| <60 | 26 | |
| T3 | 57 | |
| ≤T2 | 20 | |
| N0 | 35 | |
| N1 | 42 | |
| M0 | 73 | |
| M1 | 4 | |
| ≥II | 63 | |
| I | 14 | |
| Head/Neck | 40 | |
| Body/Tail | 37 | |
| Yes | 49 | |
| No | 28 | |
| Yes | 10 | |
| No | 67 | |
| III | 26 | |
| ≤II | 51 |
Figure 1CD206 was upregulated in PDAC. A. Representative images of CD206 expression in PDAC. B. CD206 expression in the cancerous tissues and paired normal tissues. C. Kaplan-Meier survival curves of patients with PDAC. OS based on levles of CD206 expression in PDAC.
PKM2 and CD206 expression in the cancerous tissues and the adjacent tissues
| Number | PKM2 | P value | CD206 | P value | |||
|---|---|---|---|---|---|---|---|
| Negative | Positive | Negative | Positive | ||||
| 77 | 37 | 40 | p<0.05 | 35 | 42 | p<0.05 | |
| 77 | 57 | 20 | 54 | 23 | |||
Correlation between PKM2, CD206 and clinicopathologic features of PDAC
| Factor | PKM2 | P value | CD206 | P value | ||
|---|---|---|---|---|---|---|
| Negative | Positive | Negative | Positive | |||
| Male | 24 | 27 | 0.807 | 23 | 28 | 0.93 |
| Female | 13 | 13 | 12 | 14 | ||
| ≥60 | 27 | 24 | 0.2291 | 25 | 26 | 0.379 |
| <60 | 10 | 16 | 10 | 16 | ||
| T3 | 29 | 28 | 0.402 | 25 | 32 | 0.635 |
| ≤T2 | 8 | 12 | 10 | 10 | ||
| N0 | 18 | 17 | 0.298 | 10 | 25 | 0.007 |
| N1 | 19 | 23 | 25 | 17 | ||
| M0 | 36 | 37 | 0.664 | 33 | 40 | 1 |
| M1 | 1 | 3 | 2 | 2 | ||
| ≥II | 24 | 39 | 0.0002 | 27 | 36 | 0.331 |
| I | 13 | 1 | 8 | 6 | ||
| Head/Neck | 17 | 22 | 0.137 | 18 | 22 | 0.934 |
| Body/Tail | 20 | 18 | 17 | 20 | ||
| Yes | 22 | 20 | 0.698 | 25 | 24 | 0.194 |
| No | 15 | 20 | 10 | 18 | ||
| Yes | 9 | 1 | 0.012 | 2 | 8 | 0.164 |
| No | 28 | 39 | 33 | 34 | ||
| III | 12 | 24 | 0.056 | 13 | 13 | 0.567 |
| ≤II | 35 | 16 | 22 | 29 | ||
Univariate and multivariate survival analysis of PDAC patients
| Factor | OS median (range) | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | P value | HR | 95%CI | P value | |||
| Male | 19.0(1.0-47.0) | 1.054 | 0.555-2.004 | 0.871 | ||||
| Female | 20.0(3.0-46.0) | 1 | ||||||
| ≥60 | 22.0(1.0-47.0) | 0.677 | 0.365-1.254 | 0.215 | ||||
| <60 | 15.5(2.0-46.0) | 1 | ||||||
| T3 | 17.8(1.7-47.6) | 1.778 | 0.822-3.845 | 0.144 | ||||
| ≤T2 | 23.0(3.0-46.0) | 1 | ||||||
| N0 | 22.3(2.9-47.6) | 1.279 | 0.694-2.357 | 0.431 | ||||
| N1 | 17.(1.7-45.8) | 1 | ||||||
| M0 | 18.4(1.7-47.6) | 0.658 | 0.175-3.005 | 0.658 | ||||
| M1 | 23.2(12.4-40.3) | 1 | ||||||
| ≥II | 15.6(1.7-47.6) | 3.052 | 1.087-8.567 | 0.034 | 2.899 | 1.731-4.855 | <.0001 | |
| I | 31.1(12.6-46.5) | 1 | 1 | |||||
| Head and Neck | 16.4(1.7-47.6) | 1.204 | 0.657-2.209 | 0.548 | ||||
| Body and Tail | 23.1(2.9-46.4) | 1.000 | ||||||
| Yes | 13.6(1.7-46.5) | 2.171 | 1.089-4.328 | 0.028 | 1.592 | 0.989-2.560 | 0.055 | |
| No | 23.7(3.1-47.6) | 1.000 | 1.000 | |||||
| Yes | 7.9(3.1-46.5) | 1.926 | 1.198-3.095 | 0.007 | 1.583 | 0.984-2.546 | 0.058 | |
| No | 22.3(1.7-47.6) | 1.000 | 1.000 | |||||
| III | 12.1(1.7-44.6) | 2.374 | 1.290-4.368 | 0.005 | 2.519 | 1.534-4.137 | 0.000 | |
| <II | 23.2(4.0-47.6) | 1.000 | 1.000 | |||||
| Positive | 12.5(1.7-46.5) | 2.326 | 1.428-3.788 | 0.001 | 2.117 | 1.309-3.426 | 0.002 | |
| Negative | 23.7(2.9-47.6) | 1.000 | 1.000 | |||||
| Positive | 9.4(1.7-46.5) | 1.861 | 1.159-2.988 | 0.010 | 1.595 | 0.992-2.566 | 0.054 | |
| Negative | 23.2(2.9-47.6) | 1.000 | 1.000 | |||||
| PKM+/CD206+ | 7.3(1.7-46.5) | 2.558 | 1.556-4.205 | 0.000 | 3.349 | 1.956-5.735 | 0.001 | |
| All others | 23.1(2.9-47.6) | 1.000 | 1.000 | |||||
Figure 2PKM2 was overexpression in PDAC. A. Representative images of PKM2 expression in PDAC. B. PKM2 expression in the cancerous tissues and paired normal tissues. C. Kaplan-Meier survival curves of patients with PDAC. Overall survival (OS) based on PKM2 expression in PDAC. D. Overall survival based on PKM2 expression in PDAC from TCGA database by GEPIA online analysis.
Figure 3Positive correlation between CD206 and PKM2 in PDAC. A. Representative images depicted the positive correlation between CD206 and PKM2 in the series sections of PDAC. B and C. Kaplan-Meier survival curves of patients with PDAC. OS based on CD206 and PKM2 expression in PDAC.
the correlation between PKM2 and CD206 in PDAC
| Tumor tissues | PKM2 expression | Correlation coefficient | P value | |||
|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | |||
| 9 | 1 | 2 | 0 | rs=0.175 | 0.03 | |
| 2 | 12 | 7 | 2 | |||
| 3 | 9 | 22 | 0 | |||
| 0 | 1 | 1 | 6 | |||
Figure 4Overexpression of PKM2 in PDAC promotes macrophage toward M2 polarization. A. Images indicated the effects of PKM2 knockdown in CAPAN2 and ASPC-1 cells. B and C. PBMC-derived macrophages (MΦ) were co-cultured with PDAC cells with PKM2 kncokdown. And then the expression of CD206 in macrophages was evaluated by detecting the mean fluorescence intensity (MFI) using FACS. D-G. MΦ was co-cultured with PDAC cells with PKM2 agonist treatment. And then the expression of CD206, CD163 and CD86 in macrophages was evaluated by detecting the mean fluorescence intensity (MFI) using FACS. Data, mean±SEM; *** p < 0.001.
Figure 5Proposed model links M2 macrophages to PKM2 in PDAC. PDAC cells with PKM2 overexpression resulted in lactate secretion, which then favors M2 macrophages in phenotype. Inversely, M2 macrophages 're-educate' the neoplastic cells toward a more aggressive phenotype by secreting bioactive factors.